| Description |
Recombinant Human VIPR2 Protein is expressed from HEK293 with mFc tag at the C-terminus.It contains Glu24-Val126. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
P41587 |
| Target Symbol |
VIPR2 |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-mFc |
| Expression Range |
Glu24-Val126 |
| Mol. Weight |
The protein has a predicted MW of 37.35 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Effects of vasoactive intestinal peptide (VIP) on T cell migration are mediated by structurally distinct types I (VIPR1) and II (VIPR2) G protein-associated receptors. The two receptor types were proposed to transduce opposite effects on human T cells, since cytokine-induced chemotaxis of VIPR1-bearing HuT 78 human T cells, in contrast to T cells that express VIPR2, was inhibited by VIP. |
